#United States #San Diego #Class Action #Inc. #DexCom #G6 and G7

Overview of the Allegations

Recent legal action has been initiated against Dexcom, Inc. (NASDAQ: DXCM), a company renowned for its continuous glucose monitoring (CGM) systems that assist in diabetes management. Robbins LLP has filed a class action lawsuit on behalf of investors who acquired Dexcom's securities from July 26, 2024, until September 17, 2025. The lawsuit comes in response to serious concerns regarding the safety and reliability of the company’s CGM systems, notably the G6 and G7 models.

Dexcom's Product Line

Dexcom is at the forefront of diabetes technology, primarily focusing on the development of CGM systems that offer real-time glucose monitoring. The G6, launched in 2018, and the more recent G7, unveiled in 2023, are significant products in their lineup. However, these devices are now under scrutiny due to alleged undisclosed material design changes that have raised potential health risks for users relying on these devices for accurate glucose readings.

Key Allegations

According to the complaint filed by Robbins LLP, several serious allegations have been leveled against Dexcom:

1. Undisclosed Design Changes: Dexcom reportedly implemented significant design modifications to both the G6 and G7 devices without proper authorization from the U.S. Food and Drug Administration (FDA).
2. Compromised Reliability: These unauthorized changes have reportedly made the G6 and G7 systems less reliable, introducing a substantial health risk for users who depend on the devices for precise glucose readings.
3. Exaggerated Claims: It is alleged that the company overstated the enhancements introduced to the G7 model regarding its functionality and reliability.
4. Downplayed Risks: Dexcom is accused of minimizing the actual scope and severity of the risks tied to the altered G7 devices.
5. Increased Regulatory Scrutiny: The allegations suggest that these issues have exposed Dexcom to heightened regulatory scrutiny and potential enforcement actions, along with significant legal, reputational, and financial consequences.

The Hunterbrook Report

On September 18, 2025, Hunterbrook published a damning report titled “Dexcom’s Fatal Flaws,” which brought to light the more severe consequences associated with the G7 device than previously acknowledged. Utilizing documents obtained through a Freedom of Information Act request, the report pointed to incidents where users experienced hospitalization or even death following incorrect glucose readings, linking these tragedies to the alleged deficiencies in the G7 devices. Following the publication of this report, Dexcom’s stock experienced a significant drop of $8.99 per share (approximately 11.76%), closing at $67.45 on September 19, 2025.

Next Steps for Investors

Affected investors who wish to become lead plaintiffs in the class action must file their documents with the court by December 29, 2025. A lead plaintiff represents the interests of the entire class and directs the litigation process. However, participation in the lawsuit is not mandatory to be eligible for a recovery, allowing investors the option to remain as absent class members if they choose to take no action.

Robbins LLP's Role

Robbins LLP, established in 2002, has built a reputable standing in shareholder rights litigation, assisting stockholders in recovering losses and ensuring corporate accountability. The firm operates solely on a contingency fee basis, meaning that shareholders do not incur fees or expenses unless they receive a recovery. Investors are encouraged to engage with Robbins LLP for more information about this class action or to sign up for updates on similar corporate misconduct.

Conclusion

As the lawsuit progresses, investors in Dexcom, Inc. must remain informed about their potential rights and the developments within this class action case. The implications of this legal action could extend far beyond immediate shareholder interests, affecting the consumers relying on Dexcom's products for their health management.